Alessandro Fanzani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1185058/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
3	Molecular and cellular mechanisms of skeletal muscle atrophy: an update. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 163-179.	2.9	264
4	Autophagic Degradation Contributes to Muscle Wasting in Cancer Cachexia. American Journal of Pathology, 2013, 182, 1367-1378.	1.9	212
5	Muscle Wasting and Impaired Myogenesis in Tumor Bearing Mice Are Prevented by ERK Inhibition. PLoS ONE, 2010, 5, e13604.	1.1	154
6	Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems. Toxicology and Applied Pharmacology, 2011, 250, 312-321.	1.3	59
7	Clozapine-Induced Alteration of Glucose Homeostasis in the Rat: The Contribution of Hypothalamic-Pituitary-Adrenal Axis Activation. Neuroendocrinology, 2007, 85, 61-70.	1.2	57
8	Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1717-1730.	1.2	56
9	Iron, Oxidative Damage and Ferroptosis in Rhabdomyosarcoma. International Journal of Molecular Sciences, 2017, 18, 1718.	1.8	41
10	Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma. Laboratory Investigation, 2015, 95, 585-602.	1.7	37
11	Cobalt triggers necrotic cell death and atrophy in skeletal C2C12 myotubes. Toxicology and Applied Pharmacology, 2013, 271, 196-205.	1.3	32
12	Implications for the mammalian sialidases in the physiopathology of skeletal muscle. Skeletal Muscle, 2012, 2, 23.	1.9	29
13	NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. Journal of Cancer Research and Clinical Oncology, 2019, 145, 881-893.	1.2	28
14	Rhabdomyosarcomas: an overview on the experimental animal models. Journal of Cellular and Molecular Medicine, 2012, 16, 1377-1391.	1.6	27
15	Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 393-409.	1.2	25
16	Insulin-like growth factor 1 signaling regulates cytosolic sialidase Neu2 expression during myoblast differentiation and hypertrophy. FEBS Journal, 2006, 273, 3709-3721.	2.2	24
17	Muscular dystrophies share pathogenetic mechanisms with muscle sarcomas. Trends in Molecular Medicine, 2013, 19, 546-554.	3.5	22
18	Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines. Cancer Letters, 2019, 461, 90-101	3.2	22

Alessandro Fanzani

#	Article	IF	CITATIONS
19	Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma. European Journal of Cancer, 2011, 47, 761-772.	1.3	21
20	Point mutated caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 468-479.	1.8	21
21	Caveolin-1 promotes radioresistance in rhabdomyosarcoma through increased oxidative stress protection and DNA repair. Cancer Letters, 2021, 505, 1-12.	3.2	21
22	Melatonin action in tumor skeletal muscle cells: an ultrastructural study. Acta Histochemica, 2016, 118, 278-285.	0.9	20
23	Melatonin decreases cell proliferation, impairs myogenic differentiation and triggers apoptotic cell death in rhabdomyosarcoma cell lines. Oncology Reports, 2015, 34, 279-287.	1.2	19
24	Caveolin-1, Caveolin-2 and Cavin-1 are strong predictors of adipogenic differentiation in human tumors and cell lines of liposarcoma. European Journal of Cell Biology, 2016, 95, 252-264.	1.6	19
25	Characterization of the APâ€1 μ1A and μ1B adaptins in zebrafish (<i>Danio rerio</i>). Developmental Dynamics, 2010, 239, 2404-2412.	0.8	18
26	Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization. Journal of Biomedical Science, 2020, 27, 90.	2.6	18
27	Uncovering metabolism in rhabdomyosarcoma. Cell Cycle, 2016, 15, 184-195.	1.3	17
28	Caveolin-1 enhances metastasis formation in a human model of embryonal rhabdomyosarcoma through Erk signaling cooperation. Cancer Letters, 2019, 449, 135-144.	3.2	17
29	Phosphocaveolin-1 Enforces Tumor Growth and Chemoresistance in Rhabdomyosarcoma. PLoS ONE, 2014, 9, e84618.	1.1	17
30	Hypertrophy and atrophy inversely regulate Caveolin-3 expression in myoblasts. Biochemical and Biophysical Research Communications, 2007, 357, 314-318.	1.0	15
31	The cytosolic sialidase Neu2 is degraded by autophagy during myoblast atrophy. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 817-828.	1.1	14
32	MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. International Journal of Molecular Sciences, 2021, 22, 10671.	1.8	14
33	Phenotypic behavior of C2C12 myoblasts upon expression of the dystrophyâ€related caveolinâ€3 P104L and TFT mutants. FEBS Letters, 2007, 581, 5099-5104.	1.3	13
34	Differentiation of human rhabdomyosarcoma RD cells is regulated by reciprocal, functional interactions between myostatin, p38 and extracellular regulated kinase signalling pathways. European Journal of Cancer, 2011, 47, 1095-1105.	1.3	13
35	Caveolins in rhabdomyosarcoma. Journal of Cellular and Molecular Medicine, 2011, 15, 2553-2568.	1.6	13
36	Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, inÂvitro and inÀvivo, the alveolar phenotype subtype. International Journal of Radiation Biology, 2021, 97, 943-957.	1.0	13

#	Article	IF	CITATIONS
37	Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiation. International Journal of Radiation Biology, 2020, 96, 823-835.	1.0	12
38	The enzymatic activity of sialidase Neu2 is inversely regulated during in vitro myoblast hypertrophy and atrophy. Biochemical and Biophysical Research Communications, 2008, 370, 376-381.	1.0	10
39	<p>Animal models of well-differentiated/dedifferentiated liposarcoma: utility and limitations</p> . OncoTargets and Therapy, 2019, Volume 12, 5257-5268.	1.0	10
40	The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells. Pharmaceuticals, 2019, 12, 129.	1.7	8
41	Defective myogenic differentiation of human rhabdomyosarcoma cells is characterized by sialidase Neu2 loss of expression. Cell Biology International, 2009, 33, 1020-1025.	1.4	7
42	L6E9 Myoblasts Are Deficient of Myostatin and Additional TGF-Î ² Members Are Candidates to Developmentally Control Their Fiber Formation. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-9.	3.0	7
43	Urocortin Induces Phosphorylation of Distinct Residues of Signal Transducer and Activator of Transcription 3 (STAT3) via Different Signaling Pathways. Medical Science Monitor Basic Research, 2019, 25, 139-152.	2.6	6
44	Focus on the role of Caveolin and Cavin protein families in liposarcoma. Differentiation, 2017, 94, 21-26.	1.0	5
45	Cavin-2 is a specific marker for detection of well-differentiated liposarcoma. Biochemical and Biophysical Research Communications, 2017, 493, 660-665.	1.0	5
46	MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line. PLoS ONE, 2015, 10, e0130287.	1.1	2